Tetra Med Sciences Pvt Ltd, a subsidiary of Tetra Global in St Louis, USA, has commenced R&D centre operations in Hyderabad.
The initial focus will be on developing molecules with their intermediates for active pharmaceutical ingredients (APIs) and others drugs going off-patent for now and over the next five to ten years.
The company aims to work on API and other domains; and plans to acquire their own production facility centre at the earliest but for now it has signed up with a third party facility for their immediate needs. “Recognising the impact of API supply chain shortage and cost competency of the pharma sector and encouraged by Govt’s support for women entrepreneurs, we decided to work in new molecules development starting with intermediates for API,’’ Lathaa Subramanian, Founder, Tetra Med Sciences said in a release.
Published on August 27, 2021
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.